Canada: Minister's Decision To Issue NOC Without Notice To First Person For Cross-Referenced Drug Submission Held Reasonable By The FCA

Case: Teva Canada Limited et al v Pfizer Canada Inc et al, 2016 FCA 248

Drug: AROMASIN® (exemestane) and REMICADE® (infliximab)

Nature of case: Appeal from a judicial review setting aside a decision of the Minister of Health to not require notice under section 5 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133

Successful party: Teva Canada Limited, Hospira Healthcare Corporation and The Minister of Health

Date of decision: Oct. 12, 2016


This appeal relates to two generic drug submissions for two different products: exemestane and infliximab. Both submissions cross-referenced the submission of another generic company that had received a Notice of Compliance (NOC). The Minister of Health (Minister) issued NOCs for the two generic products without requiring notice to the innovator company in the form of a Notice of Allegation (NOA).

In both cases, the innovator companies brought an application for judicial review and the Minister's decisions were set aside. The Minister and the respective generic manufacturers appealed. The appeals were allowed by the Federal Court of Appeal. The FCA held that in the circumstances the generic companies were not required to serve NOAs.


This decision results from a consolidation of four appeals arising from the Federal Court setting aside the Minister's decision to issue NOCs to two generic companies relating to exemestane and infliximab. The issue in both appeals is whether the Minister was permitted to issue NOCs to the generic companies without requiring them to address relevant patents on the Patent Register pursuant to section 5 of the Patented Medicines (Notice of Compliance) Regulations (Regulations).

Exemestane. Pfizer Canada Inc. manufactures exemestane under the name AROMASIN®. Generic Medical Partners Inc. (GMP) filed a submission seeking approval to market a generic version of exemestane and served an NOA on Pfizer. Pfizer did not seek a prohibition order and an NOC subsequently issued to GMP.

After GMP received an NOC, Teva Canada Limited filed a submission for a generic version of exemestane that cross-referenced GMP's submission. Teva's submission included a certification that all aspects of its product were identical to GMP's, except for the names of the manufacturer and the product, and an authorization from GMP to access GMP's submission.

The Minister issued an NOC to Teva without requiring it to serve an NOA on Pfizer. As we reported, Pfizer successfully brought an application for judicial review, and the Minister's decision was set aside.

Infliximab. Janssen Inc. manufactures infliximab under the name REMICADE®. Celltrion Healthcare Co. Ltd. filed a submission seeking approval to market a biosimilar under the name INFLECTRA®. At that time, no patent was listed on the Patent Register in respect of REMICADE® and the NOC issued. Janssen subsequently listed a patent on the register for infliximab.

After Celltrion received an NOC and Janssen listed its patent on the Register, Hospira Healthcare Corporation filed a submission that cross-referenced Celltrion's submission. Hospira's submission certified that it had entered into a licensing agreement with Celltrion, that all aspects of Hospira's product were identical to Celltrion's except for the manufacturer's name and included an authorization from Celltrion to cross-reference Celltrion's submission.

The Minister issued the NOC to Hospira without requiring that an NOA be served on Janssen. The Minister's decision was set aside by the Federal Court on consent, to allow the appeals to be heard with those for exemestane.

The standard of review is reasonableness

The FCA reversed the Federal Court's holding that the applicable standard of review was correctness. The FCA agreed with the Federal Court that the presumptive standard of review is reasonableness. Whether section 5 is engaged, the FCA held, is a question of mixed fact and law within the expertise of the Minister, and reasonableness applies where, as in this case, the statute or regulations at issue are closely related to the decision maker's function.

Furthermore, the FCA disagreed with the Federal Court that the presumption was rebutted in these cases, holding that there was no evidence of an intention by Parliament to have the Minister's decisions reviewed on a less deferential standard. Therefore, the Minister's decisions should be reviewed on the standard of reasonableness.

The Minister's decision was reasonable

Having determined the correct standard of review, the FCA went on to review the reasonableness of the Minister's decision.

The FCA found that it is relevant to consider whether the generic company took advantage of the early working exception. This is particularly relevant to infliximab as there was no patent listed when Celltrion obtained its NOC, and therefore as a matter of law there could be no early working.

The FCA also considered the interpretation of the word "submission," which requires consideration of each individual submission. Consistent with jurisprudence interpreting the term "submission" in the context of section 4 of the Regulations, the FCA held that the focus should be on the drug product itself and whether the changes reflected in the submission give rise to a new or different basis for asserting that a particular product is infringing. In both cases, the generic companies sought approval for products that were identical to a previously approved generic product and any potential infringement could be addressed in infringement proceedings.

The FCA found that on the facts of these cases, the generic companies did not need to serve NOAs on the innovator companies.


Teva Canada Limited et al v Pfizer Canada Inc et al, 2016 FCA 248

Federal Court decision (exemestane): Pfizer Canada Inc v Canada (Health), 2014 FC 1243

About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see

Law around the world

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.